Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE) traded down 4.9% during trading on Friday . The company traded as low as $39.32 and last traded at $39.40. 55,588 shares were traded during trading, a decline of 87% from the average session volume of 443,642 shares. The stock had previously closed at $41.43.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MAZE shares. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. HC Wainwright raised their price target on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, December 3rd. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Friday, December 19th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $43.38.

Maze Therapeutics Stock Down 6.6%

The stock has a market cap of $1.86 billion and a P/E ratio of -1.85. The business’s 50-day simple moving average is $36.81 and its two-hundred day simple moving average is $24.70.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 45,000 shares of Maze Therapeutics stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $2,936,544.00. Following the sale, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 132,500 shares of company stock valued at $5,371,980 in the last 90 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MAZE. CWM LLC bought a new stake in shares of Maze Therapeutics during the second quarter valued at about $28,000. Ameritas Investment Partners Inc. boosted its position in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the period. Corebridge Financial Inc. purchased a new position in Maze Therapeutics during the first quarter valued at approximately $48,000. Russell Investments Group Ltd. increased its holdings in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Maze Therapeutics during the 3rd quarter worth approximately $52,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.